Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
about
The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patientsCancerous Inhibitor of PP2A Silencing Inhibits Proliferation and Promotes Apoptosis in Human Multiple Myeloma Cells.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.Computational identification of microRNAs and their targets in liver cirrhosis.Therapeutic Targeting of PP2A.Phosphorylated AKT expression in tumor-adjacent normal tissue is associated with poor prognosis in patients with hepatocellular carcinoma.CIP2A acts as a scaffold for CEP192-mediated microtubule organizing center assembly by recruiting Plk1 and aurora A during meiotic maturation.Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion.IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
P2860
Q33885293-A80270C2-88FE-4DC2-ABCD-ED5E63418A6CQ36814489-6CEC2B40-F9EC-4AFD-AB76-053E0AB691F5Q38678579-42FB7231-A60F-4F02-BBD1-91AA25E4E86EQ38891984-713261C1-A909-4DDA-9CE7-FFF584DEDA0DQ47099635-27DC18AA-9FE7-4A61-A2AD-E28C8C2C2B3AQ47436859-E5A0ED3D-5D18-42AF-B976-E93678738504Q47552146-9B51162A-B2D7-47E0-A316-00CE0E5C3797Q47649638-6278C5D7-7182-4E87-99E2-7C39C81576BEQ48064023-7D8F867F-F12D-4831-A819-4249E427A7A4Q48128686-8CD015A7-00F5-4060-8A1B-737F8E7082B4Q48192654-55DFBCE2-4E3E-4E4C-8ACC-96014CB5C8FAQ54966891-6E52BC22-27B2-4FDB-B937-F3E6778AD1CB
P2860
Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Erlotinib derivative inhibits ...... tivate protein phosphatase 2A.
@ast
Erlotinib derivative inhibits ...... tivate protein phosphatase 2A.
@en
Erlotinib derivative inhibits ...... tivate protein phosphatase 2A.
@nl
type
label
Erlotinib derivative inhibits ...... tivate protein phosphatase 2A.
@ast
Erlotinib derivative inhibits ...... tivate protein phosphatase 2A.
@en
Erlotinib derivative inhibits ...... tivate protein phosphatase 2A.
@nl
prefLabel
Erlotinib derivative inhibits ...... tivate protein phosphatase 2A.
@ast
Erlotinib derivative inhibits ...... tivate protein phosphatase 2A.
@en
Erlotinib derivative inhibits ...... tivate protein phosphatase 2A.
@nl
P2093
P2860
P356
P1476
Erlotinib derivative inhibits ...... ctivate protein phosphatase 2A
@en
P2093
P2860
P356
10.1038/CDDIS.2014.325
P577
2014-07-31T00:00:00Z